| Page 1426 | Kisaco Research
 

Euicheol Lim

Research Fellow, System Architect
SK Hynix

Eui-cheol Lim is a Research Fellow and leader of Solution Advanced Technology team in SK Hynix. He received the B.S. degree and the M.S. degree from Yonsei University, Seoul, Korea, in 1993 and 1995, and the Ph.D. degree from Sungkyunkwan University, suwon, Korea in 2006. Dr.Lim joined SK Hynix in 2016 as a system architect in memory system R&D. Before joining SK Hynix, he had been working as an SoC architect in Samsung Electronics and leading the architecture of most Exynos mobile SoC.

Euicheol Lim

Research Fellow, System Architect
SK Hynix

Euicheol Lim

Research Fellow, System Architect
SK Hynix

Eui-cheol Lim is a Research Fellow and leader of Solution Advanced Technology team in SK Hynix. He received the B.S. degree and the M.S. degree from Yonsei University, Seoul, Korea, in 1993 and 1995, and the Ph.D. degree from Sungkyunkwan University, suwon, Korea in 2006. Dr.Lim joined SK Hynix in 2016 as a system architect in memory system R&D. Before joining SK Hynix, he had been working as an SoC architect in Samsung Electronics and leading the architecture of most Exynos mobile SoC. His recent interesting points are memory and storage system architecture with new media memory and new memory solution such as CXL memory and Processing in Memory. In particular, he is proposing a new computing architecture based on PIM, which is more efficient and flexible than existing AI accelerators, to process generative AI and LLM (large language Model) that is currently causing a sensation.

 

LaTonya Kilpatrick

Worldwide Director of Technology, Early Research Oral Care, Devices, and Clinical Methods Development
Colgate Palmolive Co

LaTonya Kilpatrick-Liverman leads the Early Research Oral Care, Devices, and Clinical Methods group at Colgate Palmolive Co.  She and her Team are responsible for exploring current and emerging technologies in biological and related interdisciplinary sciences to assess wellness states and develop targeted and personalized solutions to improve overall health.  Her Team is also responsible for developing advanced therapies and devices to prevent disease and improve and monitor health.

LaTonya Kilpatrick

Worldwide Director of Technology, Early Research Oral Care, Devices, and Clinical Methods Development
Colgate Palmolive Co

LaTonya Kilpatrick

Worldwide Director of Technology, Early Research Oral Care, Devices, and Clinical Methods Development
Colgate Palmolive Co

LaTonya Kilpatrick-Liverman leads the Early Research Oral Care, Devices, and Clinical Methods group at Colgate Palmolive Co.  She and her Team are responsible for exploring current and emerging technologies in biological and related interdisciplinary sciences to assess wellness states and develop targeted and personalized solutions to improve overall health.  Her Team is also responsible for developing advanced therapies and devices to prevent disease and improve and monitor health.

LaTonya has over 30 years of experience conducting research in skin and oral biology. She is the author of several patents, book chapters, and journal articles, and has served on the Editorial Advisory Board of the International Journal of Cosmetic Science, the Chemistry and Chemical Biology Industrial Advisory Board at Rutgers University, and on the Biomaterials Symposium Advisory Board at Rutgers University.

LaTonya has volunteered in a number of education based outreach programs sponsored by Colgate Palmolive, the American Chemical Society, and various community groups.  She finds joy leveraging every opportunity to give back and share her experiences.

LaTonya joined the Colgate Piscataway GTC in 1992.  She holds a BA degree in Chemistry from Hampton University and a PhD degree in Chemistry from Princeton University.

 

Yvonne Kapila

Professor, Chair Division of Periodontology, Department of Orofacial Sciences,
University of California San Francisco

Yvonne Kapila is a clinician-scientist with over 20 years of experience studying the basic mechanisms and translational and clinical aspects of periodontal disease pathogenesis and head and neck cancer carcinogenesis using in vitro and in vivo models and human clinical studies.

Her early research focused on understanding the basic extracellular matrix (ECM) processes and host-microbial mechanisms that govern head and neck cancer tumorigenesis and periodontal disease pathogenesis.

Yvonne Kapila

Professor, Chair Division of Periodontology, Department of Orofacial Sciences,
University of California San Francisco

Yvonne Kapila

Professor, Chair Division of Periodontology, Department of Orofacial Sciences,
University of California San Francisco

Yvonne Kapila is a clinician-scientist with over 20 years of experience studying the basic mechanisms and translational and clinical aspects of periodontal disease pathogenesis and head and neck cancer carcinogenesis using in vitro and in vivo models and human clinical studies.

Her early research focused on understanding the basic extracellular matrix (ECM) processes and host-microbial mechanisms that govern head and neck cancer tumorigenesis and periodontal disease pathogenesis.

Kapila made important discoveries focused on the cell and molecular biology mechanisms that regulate anoikis; programmed cell death or apoptosis triggered by the loss of extracellular matrix contacts.

Kapila's recent research has extended to omics approaches and biomarker discovery for head and neck cancer using metabolomics and microbiome approaches.

Her related work in sirtuin biology and oral cancer were seminal in showing that sirtuin 3, a metabolic enzyme, regulates and promotes oral cancer tumorigenesis.

Recently funded projects in her lab have focused on host-microbial interactions and the novel role of bacteriocins in biomedical applications, including as modulators of tumorigenesis and disease-associated biofilms and the oral microbiome.

 

Rob Telson

Vice President of Ecosystems & Partnerships
BrainChip

Rob Telson brings over 25 years of sales expertise in licensing intellectual property and selling EDA technology across multiple vertical markets. He has had success developing sales and support organizations at small, midsize, and large companies. At ARM, a global semiconductor and software design company, Rob was Vice President of Foundry Sales worldwide and prior was Vice President of Sales for the Americas. At Synopsys, he was responsible for building and developing a business focused on disruptive technologies in the semiconductor space.

Rob Telson

Vice President of Ecosystems & Partnerships
BrainChip

Rob Telson

Vice President of Ecosystems & Partnerships
BrainChip

Rob Telson brings over 25 years of sales expertise in licensing intellectual property and selling EDA technology across multiple vertical markets. He has had success developing sales and support organizations at small, midsize, and large companies. At ARM, a global semiconductor and software design company, Rob was Vice President of Foundry Sales worldwide and prior was Vice President of Sales for the Americas. At Synopsys, he was responsible for building and developing a business focused on disruptive technologies in the semiconductor space. Rob has been impactful on driving the growth and demand of BrainChip’s technology leading Worldwide Sales and Marketing and now developing and leading the Ecosystem and Partnerships at BrainChip. Rob holds a BS in political science from the University of Arizona and a Program for Leadership Development certificate from Harvard Business School.

 

Sabrina Martucci Johnson

President and CEO
DARÉ Bioscience

Sabrina Martucci Johnson is a life sciences executive with a record of achievement in building successful companies, launching innovative products into specialty markets, delivering returns on shareholder investments, and implementing complex directional change.   

 

Sabrina Martucci Johnson

President and CEO
DARÉ Bioscience

Sabrina Martucci Johnson

President and CEO
DARÉ Bioscience

Sabrina Martucci Johnson is a life sciences executive with a record of achievement in building successful companies, launching innovative products into specialty markets, delivering returns on shareholder investments, and implementing complex directional change.   

 

Sabrina is committed to advancing innovation in women’s health. She is the Founder and CEO of DARÉ Bioscience (NASDAQ:DARE), a clinical-stage biopharmaceutical company driven by a mission to identify, develop and bring to market a diverse portfolio of novel therapies that expand treatment options, improve outcomes and facilitate convenience for women.  Prior to founding DARÉ, Sabrina was President of WomanCare Global Trading, a global provider of women’s health products, CFO/CAO of the California Institute for Biomedical Research, CFO/COO of Cypress Bioscience, Inc. (NASDAQ:CYPB), held marketing and sales positions with Advanced Tissue Sciences, and began her career in the biotechnology industry as a research scientist with Baxter Healthcare, Hyland Division, working on the recombinant factor VIII program.  

 

Sabrina has a Master of International Management with honors from the American Graduate School of International Management (Thunderbird); a MSc. in Biochemical Engineering from the University of London, University College London; and a BSc. in Biomedical Engineering from Tulane University, magna cum laude.  

 

Sabrina currently serves on the boards of ATAI Life Sciences, a publicly-traded clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and Aethlon Medical, Inc., a publicly-traded company developing immunotherapeutic technologies to combat infectious disease and cancer, BIOCOM, as Vice President of Industry, the Clearity Foundation as Chair, and the YWCA of San Diego County as Past President. Additionally, Sabrina serves on the Board of Advisors of Tulane University School of Science & Engineering and on the Audit Committee of Project Concern International. 

Ms. Johnson was honored by Athena, a San Diego-based business organization championing women executives and rising managers in science, technology, engineering and mathematics, with the Individual in Life Science award in 2017 and the same year received the “Moxie” for her grit and determination and positive impact in the community from the award-winning MOXIE Theatre, a Southern California theatre dedicated to producing diverse and honest images of women using the art of theatre.  She was an E&Y Entrepreneur of the Year San Diego finalist in 2018 and in 2019 was recognized as an entrepreneur in the PharmaVoice 100 and honored as 2019 Director of the Year in the Emerging Board Leader category by the San Diego Corporate Directors Forum. 

 

Cyril Vancura

Partner
imec.xpand

Cyril Vancura is Partner at imec.xpand, an independently managed value-add venture capital fund that focuses on hardware-based nanotechnology innovations where imec technology, expertise, network and infrastructure will play a differentiating role. Based in Leuven, Belgium, Cyril is focusing predominantly on deeptech investment opportunities in Europe and the US. Before joining imec.xpand, Cyril was Investment Principal at Robert Bosch Venture Capital GmbH (RBVC), the corporate venture arm of Robert Bosch GmbH.

Cyril Vancura

Partner
imec.xpand

Cyril Vancura

Partner
imec.xpand

Cyril Vancura is Partner at imec.xpand, an independently managed value-add venture capital fund that focuses on hardware-based nanotechnology innovations where imec technology, expertise, network and infrastructure will play a differentiating role. Based in Leuven, Belgium, Cyril is focusing predominantly on deeptech investment opportunities in Europe and the US. Before joining imec.xpand, Cyril was Investment Principal at Robert Bosch Venture Capital GmbH (RBVC), the corporate venture arm of Robert Bosch GmbH. At RBVC he was based in Germany, as well as, in the affiliate office in Silicon Valley. Cyril holds a Ph.D. and a diploma (Master Degree) in physics from the Swiss Federal Institute of Technology (ETH) in Zurich, Switzerland.

 

Moshe Tanach

Co-Founder & CEO
NeuReality

Moshe Tanach

Co-Founder & CEO
NeuReality

Moshe Tanach

Co-Founder & CEO
NeuReality
 

Dan McCreary

Distinguished Engineer in AI and Graph
Optum Technology

Dan is a distinguished engineer in AI working on innovative database architectures including document and graph databases. He has a strong background in semantics, ontologies, NLP and search. He is a hands-on architect and like to build his own pilot applications using new technologies. Dan started the NoSQL Now! Conference (now called the Database Now! Conferences). He also co-authored the book Making Sense of NoSQL, one of the highest rated books on Amazon on the topic of NoSQL. Dan worked at Bell Labs as a VLSI circuit designer where he worked with Brian Kernighan (of K&R C).

Dan McCreary

Distinguished Engineer in AI and Graph
Optum Technology

Dan McCreary

Distinguished Engineer in AI and Graph
Optum Technology

Dan is a distinguished engineer in AI working on innovative database architectures including document and graph databases. He has a strong background in semantics, ontologies, NLP and search. He is a hands-on architect and like to build his own pilot applications using new technologies. Dan started the NoSQL Now! Conference (now called the Database Now! Conferences). He also co-authored the book Making Sense of NoSQL, one of the highest rated books on Amazon on the topic of NoSQL. Dan worked at Bell Labs as a VLSI circuit designer where he worked with Brian Kernighan (of K&R C). Dan also worked with Steve Jobs at NeXT Computer.

 

Mattie Yeta

Head of Sustainability Group Strategy
DEFRA IT

Mattie Yeta

Head of Sustainability Group Strategy
DEFRA IT

Mattie Yeta

Head of Sustainability Group Strategy
DEFRA IT